ClinicalTrials.gg
Drug

Pramipexole clinical trials

Also written Mirapex and Sifrol®.

studies test it
81
open now
5
in phase 3
27
first study started
1998

How each study uses Pramipexole is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Pramipexole studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
1 Jul 1997 · MIRAPEX · NDA 020667 (FDA, Drugs@FDA)
European Union
13 Oct 1997 · Sifrol · EMEA/H/C/000133 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Pramipexole
50
Pramipexole Immediate Release
4
Pramipexole Extended Release
3
Pramipexole Dihydrochloride
3
Pramipexol Extended Release
2

Brand

Mirapex
12
Sifrol®
2

Development codes

CTC-501
1

Studies by the year they started

81 studies that test it; most in 2006 (13)

Studies that test Pramipexole, by start year
YearStudies
19982
19991
20011
20022
20034
20045
20054
200613
20077
20084
20091
20104
20114
20121
20131
20142
20171
20185
20196
20211
20222
20233
20243
20264

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
12
Phase 2
16
Phase 3
27
Phase 4
25
No phase
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 42 · Other 39

Boehringer Ingelheim (35) · Massachusetts General Hospital (3) · Region Skane (2) · National Institute of Mental Health (NIMH) (2) · Teva Pharmaceuticals USA (2) · Stanford University (2) · Clinical Academic Center (2CA-Braga) (2) · University of California, San Diego (1)

Often tested with

Tested in the same studies.

Rasagiline (2) · Bromocriptine (2) · Ropinirole (2) · Escitalopram (2) · Levodopa (2) · Carbidopa, levodopa drug combination (1) · Amisulpride (1) · Methylphenidate (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test Pramipexole.

Studies

Open first, then newest update. How each study uses Pramipexole is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 81

See all 81 studies that test Pramipexole →

As the comparator · 9 — what is tested is compared with Pramipexole

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call Pramipexole · ClinicalTrials.gg INT006736

  • MeSH (NLM) D000077487PramipexoleConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 83619PEU5TPRAMIPEXOLEConfirmed FDA, NLM, Wikidata
  • RxNorm 746741Confirmed FDA, Wikidata
  • Wikidata Q421304pramipexoleConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C66456PramipexoleOne source FDA
  • DrugBank DB00413One source Wikidata

Also registered as pramipexole dihydrochloride (UNII 3D867NP06J · RxNorm 236747) and pramipexole dihydrochloride anhydrous (UNII 4R2HD0M28N).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.